Does Rallies show 13F holders for PLRX?

Yes. Rallies tracks hedge fund and 13F ownership data for PLRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PLRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PLRX. It does not provide personalized investment advice.

PLRX (Pliant Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Pliant Therapeutics, Inc. Common Stock (PLRX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLRX trades at $1.19 with a market cap of $73.07M and a P/E ratio of -0.50. PLRX moved +5.22% today. Year to date, PLRX is -6.61%; over the trailing twelve months it is -12.41%. Its 52-week range spans $1.09 to $16.10. Analyst consensus is neutral with an average price target of $2.67. Rallies surfaces PLRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PLRX stock?

Hedge funds tracked by Rallies that own PLRX include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pliant Therapeutics, Inc. Common Stock.

PLRX Key Metrics

Key financial metrics for PLRX
Metric	Value
Price	$1.19
Market Cap	$73.07M
P/E Ratio	-0.50
EPS	$-2.43
Dividend Yield	0.00%
52-Week High	$16.10
52-Week Low	$1.09
Volume	906
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-149.34M
Gross Margin	0.00%

Top Hedge Funds Holding PLRX

Redmile Group holds 772.13K shares of PLRX, changed -52.23% as of Mar 31, 2026.

Latest PLRX News

Pliant Therapeutics Posts 4 Responders with 71% Tumor Reduction, Q2 Phase Ib Planned — Mar 1, 2026

Recent PLRX Insider Trades

Cummings Keith Lamont sold 24.00K (~$30.72K) on Jan 20, 2026.
Cheung Lily sold 7.53K (~$9.64K) on Jan 20, 2026.
Coulie Bernard sold 89.38K (~$114.40K) on Jan 20, 2026.

PLRX Analyst Consensus

5 analysts cover PLRX: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.67.

Common questions about PLRX

Who owns PLRX stock?: Hedge funds tracked by Rallies that own PLRX include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pliant Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for PLRX?: Yes. Rallies tracks hedge fund and 13F ownership data for PLRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PLRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PLRX. It does not provide personalized investment advice.